2. Search Result
Search Result
Results for "

sodium

" in MCE Product Catalog:

52

Inhibitors & Agonists

2

Fluorescent Dye

1

Biochemical Assay Reagents

6

Peptides

3

Natural
Products

Targets Recommended:
Cat. No. Product Name Target Research Areas
  • HY-132609
    Patisiran sodium

    		Small Interfering RNA (siRNA) Transthyretin (TTR) Neurological Disease
    Patisiran sodium is a double-stranded small interfering RNA that targets a sequence within the transthyretin (TTR) messenger RNA. Patisiran sodium specifically inhibits hepatic synthesis of mutant and wild-type TTR. Patisiran sodium can be used for the research of hereditary TTR amyloidosis.
  • HY-108764
    Mipomersen sodium

    ISIS 301012

    		 Others Metabolic Disease
    Mipomersen (sodium) is a second-generation 20-base phosphorothioate ASO targeted to human apoB-100.
  • HY-145725
    Baliforsen sodium

    IONIS 598769 sodium

    		 Others Others
    Baliforsen (sodium) is an antisense oligonucleotide (16 nucleotides) designed to target myotonic dystrophy protein kinase (DMPK) mRNA and research myotonic dystrophy.
  • HY-B1243
    Propoxycaine hydrochloride

    		Sodium Channel Neurological Disease
    Propoxycaine hydrochloride inhibits voltage-gated sodium channels, and thereby inhibits the ionic flux required for the initiation and conduction of impulses. Propoxycaine hydrochloride application can lead to a loss of sensation.
  • HY-109561
    Pegaptanib sodium

    EYE001; NX1838

    		 VEGFR Metabolic Disease Inflammation/Immunology
    Pegaptanib sodium is an RNA aptamer directed against vascular endothelial growth factor (VEGF)-165. Pegaptanib could be used for the study of neovascular age-related macular degeneration (AMD) .
  • HY-132613
    Lumasiran sodium

    		Small Interfering RNA (siRNA) Metabolic Disease
    Lumasiran sodium, an investigational RNA interference (RNAi) therapeutic agent, reduces hepatic oxalate production by targeting glycolate oxidase. Lumasiran sodium reduces urinary oxalate excretion, the cause of progressive kidney failure in primary hyperoxaluria type 1 (PH1) .
  • HY-107695
    Remacemide hydrochloride

    FPL 12924AA

    		 iGluR Sodium Channel Neurological Disease
    Remacemide hydrochloride (FPL 12924AA), a moderate inhibitor of the Na + channel, is a weak uncompetitive NMDA receptor antagonist with IC50s of 68 μM and 76 μM for MK-801 binding and NMDA currents, respectively. Remacemide hydrochloride is an anticonvulsant agent.
  • HY-101350
    QX-314 bromide

    		Sodium Channel Neurological Disease
    QX-314 bromide is a membrane-impermeable permanently charged sodium channel blocker.
  • HY-B1798
    Tocainide

    		Sodium Channel Cardiovascular Disease
    Tocainide hydrochloride is an orally activesodium channel blocker, it blocks the sodium channels in the pain-producing foci in the nerve membranes. Tocainide hydrochloride is a primary amine analog of lidocaine, can be used for the treatment of tinnitus.
  • HY-108505
    QX-314 chloride

    		Sodium Channel Neurological Disease
    QX-314 chloride is a membrane-impermeable permanently charged sodium channel blocker.
  • HY-145558
    Bliretrigine

    		Sodium Channel Neurological Disease
    Bliretrigine is a sodium channel blocker. Bliretrigine has the effect of relieving pain.
  • HY-D1442
    SBFI tetraammonium

    		Fluorescent Dye Others
    SBFI (tetraammonium), the tetraammonium salt of SBFI, is a sodium fluorescence indicator. SBFI (tetraammonium) is sodium-sensitive dye. The excitation wavelength is set 333 nm, and the emission wavelength is 539 nm for SBFI. Storage: protect from light.
  • HY-132818
    Idrevloride

    		Sodium Channel Others
    Idrevloride, an epithelial sodium channel (ENaC) inhibitor (WO2016133967), can be used for the research of skin disorders.
  • HY-132133
    Nav1.8-IN-1

    		Sodium Channel Inflammation/Immunology Neurological Disease
    Nav1.8-IN-1 (Compound 31) is a potent inhibitor of Na(v)1.8 sodium channel. Nav1.8-IN-1 has the potential for the research of inflammatory and neuropathic pain.
  • HY-B0834
    Indoxacarb

    (±)-Indoxacarb; DPX-JW062

    		 Sodium Channel Neurological Disease
    Indoxacarb ((±)-Indoxacarb; DPX-JW062) is a broad-spectrum oxadiazine insecticide with high insecticidal activity and low mammalian toxicity. Indoxacarb blocks insect sodium channels (Sodium Channel) in nerve preparations and isolated neurons.
  • HY-117714
    AZD-3161

    		Sodium Channel Neurological Disease
    AZD-3161 is a potent and selective blocker of NaV1.7 channel, with a pIC50 of 7.1. AZD-3161 can be used for the research of neuropathic and inflammatory pain.
  • HY-100616
    cis-ACBD

    cis-2,4-Methanoglutamate

    		 Others Neurological Disease
    cis-ACBD is a potent and selective inhibitor of the high-affinity, Na +-dependent plasma membrane glutamate transporter. cis-ACBD is a glutamate reuptake inhibitor. cis-ACBD also acts as linear competitive inhibitor of the uptake of D-[3H]aspartate.
  • HY-122001
    PF-05186462

    		Sodium Channel Neurological Disease
    PF-05186462 is a potent and selective inhibitor of human Nav1.7 voltage-dependent sodium channel, with an IC50 of 21 nM. PF-05186462 shows significant selectivity for Nav1.7 versus other sodium channels (Nav 1.1, 1.2, 1.3, 1.4, 1.5, 1.6, and 1.8). PF-05186462 can be used for the research of acute or chronic pain.
  • HY-112472
    S3969

    		Sodium Channel Metabolic Disease
    S3969 is a potent and reversible activator of the human epithelial sodium channel (hENaC). The apparent EC50 for S3969 activation of hENaC is 1.2 μm.
  • HY-B0114
    Oxcarbazepine

    GP 47680

    		 Sodium Channel Apoptosis Cancer Neurological Disease
    Oxcarbazepine is a sodium channel blocker. Oxcarbazepine significantly inhibits glioblastoma cell growth and induces apoptosis or G2/M arrest in glioblastoma cell lines. Anti-cancer and anticonvulsant effects.
  • HY-10449A
    Luseogliflozin hydrate

    TS 071 hydrate

    		 SGLT Metabolic Disease
    Luseogliflozin (TS 071) hydrate is a selective potent and orally active second-generation sodium-glucose co-transporter 2 (SGLT2) inhibitor with an IC50 of 2.26 nM. Luseogliflozin hydrate can be used for the research of type 2 diabetes mellitus (T2DM).
  • HY-N3990
    Hardwickiic acid

    (-)-Hardwikiic acid

    		 Sodium Channel Infection Neurological Disease
    Hardwickiic acid ((-)-Hardwikiic acid) is an antinociceptive compound that blocks Tetrodotoxin-sensitive voltage-dependent sodium channels. Hardwickiic acid shows insecticidal activity.
  • HY-P3777
    β-Bag cell peptide

    		Potassium Channel Neurological Disease
    β-Bag cell peptide is a neuroactive peptide. β-Bag cell peptide elevates cyclic AMP levels in the bag cell neurons. β-Bag cell peptide decreases the amplitudes of the voltage-dependent potassium currents.
  • HY-N2877
    Annonacin

    		Potassium Channel Sodium Channel Na+/K+ ATPase Calcium Channel Neurological Disease
    Annonacin is an Acetogenin and promotes cytotoxicity via a pathway inhibiting the mitochondrial complex. Annonacin is the active agent found in Annona muricata to act as an inhibitor of sodium/potassium (NKA) and sarcoplasmic reticulum (SERCA) ATPase pumps.
  • HY-100973A
    Adenosine 5′-diphosphoribose sodium

    ADP ribose sodium

    		 TRP Channel Autophagy Endocrinology Metabolic Disease
    Adenosine 5′-diphosphoribose sodium (ADP ribose sodium) is a nicotinamide adenine nucleotide (NAD +) metabolite. Adenosine 5′-diphosphoribose sodium is the most potent and primary intracellular Ca 2+-permeable cation TRPM2 channel activator. Adenosine 5′-diphosphoribose sodium also can enhance autophagy.
  • HY-16952A
    Bepridil hydrochloride hydrate

    (±)-Bepridil hydrochloride hydrate; Org 5730 hydrochloride hydrate

    		 Calcium Channel Cardiovascular Disease
    Bepridil hydrochloride hydrate ((±)-Bepridil hydrochloride hydrate) is a non-selective, long-acting Ca + channel antagonist and Na +, K + channel inhibitor, with antianginal and type I antiarrhythmic effects. Bepridil hydrochloride hydrate also acts as a cardiac Na +/Ca2 + exchange (NCX1) inhibitor. Bepridil hydrochloride hydrate can be used for the research of cardiovascular disorders.
  • HY-N6691
    Veratridine

    3-Veratroylveracevine

    		 Sodium Channel Neurological Disease
    Veratridine (3-Veratroylveracevine) is a plant neurotoxin, a voltage-gated sodium channels (VGSCs) agonist. Veratridine inhibits the peak current of Nav1.7, with an IC50 of 18.39 µM. Veratridine regulates sodium ion channels mainly by activating sodium ion channels, preventing channel inactivation and increasing sodium ion flow.
  • HY-147423
    Zandatrigine

    NBI-921352; XEN901

    		 Sodium Channel Neurological Disease
    Zandatrigine (NBI-921352) is a sodium channel protein type 8 subunit alpha (Scn8α) blocker.
  • HY-P1218
    Phrixotoxin 3

    		Sodium Channel Neurological Disease
    Phrixotoxin 3 is a potent blocker of voltage-gated sodium channels, with IC50s of 0.6, 42, 72, 288, 610 nM for NaV1.2, NaV1.3, NaV1.4, NaV1.1 and NaV1.5, respectively. Phrixotoxin 3 modulates voltage-gated sodium channels with properties similar to those of typical gating-modifier toxins, both by causing a depolarizing shift in gating kinetics and by blocking the inward component of the sodium current.
  • HY-11079
    A-803467

    		Sodium Channel Inflammation/Immunology Neurological Disease
    A-803467 is a potent and selective tetrodotoxin-resistant Nav1.8 sodium channel blocker (IC50=8 nM). A-803467 has shown significant anti-nociception in neuropathic and inflammatory pain models. A-803467 enhances the chemosensitivity of conventional anticancer agents through interaction with the ATP-binding cassette subfamily G member 2 (ABCG2) transporter.
  • HY-P1218A
    Phrixotoxin 3 TFA

    		Sodium Channel Neurological Disease
    Phrixotoxin 3 TFA is a potent blocker of voltage-gated sodium channels, with IC50s of 0.6, 42, 72, 288, 610 nM for NaV1.2, NaV1.3, NaV1.4, NaV1.1 and NaV1.5, respectively. Phrixotoxin 3 TFA modulates voltage-gated sodium channels with properties similar to those of typical gating-modifier toxins, both by causing a depolarizing shift in gating kinetics and by blocking the inward component of the sodium current.
  • HY-130187A
    Sapienic acid sodium

    		Bacterial Infection
    Sapienic acid sodium is a fatty acid commonly found on the skin and in mucosa. Sapienic acid sodium has variable antimicrobial activities against Gram-positive and Gram-negative bacteria found on the skin and in the oral cavity. Sapienic acid sodium is active against Streptococcus sanguinis, Streptococcus mitis and Fusobacterium nucleatum with MBC values of 31.3 μg/mL, 375.0 μg/mL and 93.8 μg/mL, respectively.
  • HY-B2227C
    Lactate potassium

    Lactic acid potassium

    		 Bacterial Infection Others
    Lactate (Lactic acid) potassium is used as a sodium chloride substitute in the elaboration of dry meat products. Lactate potassium (56%) and sodium diacetate (4%) mixture inhibit the development of L. sake and L. monocytogenes bacteria at 4℃ to extend the shelf life of food.
  • HY-109542
    Cyclopenthiazide

    		Others Metabolic Disease
    Cyclopenthiazide is a benzothiadiazine diuretic with antihypertensive properties. Cyclopenthiazide exerts a diuretic effect by inhibiting the reabsorption of sodium chloride and water at the distal renal tubules. Cyclopenthiazide increases the excretory capacity of the rat kidney.
  • HY-113325A
    NADP sodium hydrate

    		Endogenous Metabolite Others
    NADP sodium hydrate, a β-Nicotinamide adenine dinucleotide phosphate sodium salt, is a redox cofactor. NADP sodium hydrate is a key cofactor for electron transfer in the metabolism, being alternately oxidized (NADP +) and reduced (NADPH).
  • HY-17612
    Evenamide

    NW-3509

    		 Sodium Channel Neurological Disease
    Evenamide (NW-3509) is an orally available voltage-gated sodium channel (VGSC) blocker (Ki=0.4 µM) for the research of schizophrenia. Evenamide shows efficacy in a broad spectrum of rodent models of psychosis, mania, depression, and aggressiveness.
  • HY-150612
    (R)-STU104

    		p38 MAPK Cancer
    (R)-STU104 is a potent and orally active TAK1-MKK3 interaction inhibitor with IC50s of 0.58 μM and 4.0 μM for TNF-α and MKK3 phosphorylation. (R)-STU104 suppresses the TAK1/MKK3/p38/MnK1/MK2/elF4E signal pathways through binding with MKK3 and disrupting the TAK1 phosphorylating MKK3. (R)-STU104 can be used for researching ulcerative colitis.
  • HY-B1704
    Nisoxetine

    		Monoamine Transporter Sodium Channel Neurological Disease
    Nisoxetine is a potent and selective inhibitor of noradrenaline transporter (NET), with a Kd of 0.76 nM. Nisoxetine is an antidepressant and local anesthetic, it can block voltage-gated sodium channels.
  • HY-B1704A
    Nisoxetine hydrochloride

    		Monoamine Transporter Sodium Channel Neurological Disease
    Nisoxetine hydrochloride is a potent and selective inhibitor of noradrenaline transporter (NET), with a Kd of 0.76 nM. Nisoxetine hydrochloride is an antidepressant and local anesthetic, it can block voltage-gated sodium channels.
  • HY-122376
    S-Bioallethrin

    D-Trans-Allethrin; Esbiol

    		 Sodium Channel Neurological Disease
    S-Bioallethrin is a pyrethroid insecticide. S-Bioallethrin disrupts nerve function by modifying the gating kinetics of transitions between the conducting and nonconducting states of voltage-gated sodium channels.
  • HY-19463A
    F15845

    		Sodium Channel Cardiovascular Disease
    F 15845 is a highly effective persistent sodium current blocker. F 15845 also is a cardioprotective agent, has anti-ischemic activity and exerts short- and long-term cardioprotection after myocardial infarction. F 15845 can be used for the research of myocardium functional impairment.
  • HY-103311
    Ruthenium red

    Ammoniated ruthenium oxychloride

    		 Calcium Channel Cardiovascular Disease
    Ruthenium red (Ammoniated ruthenium oxychloride) is a polycationic dye widely used for electron microscopy (EM) of cells, tissues and vegetative bacteria. Ruthenium red strongly reacts with phospholipids and fatty acids and binds to acidic mucopolysaccharides. Ruthenium red is a L-type calcium current (ICa) blocker. Storage: protect from light.
  • HY-111662
    Fc 11a-2

    		NOD-like Receptor (NLR) Inflammation/Immunology
    Fc 11a-2, a benzimidazole compound, is an orally active and potent NLRP3 inflammasome inhibitor. Fc 11a-2 restrains the formation of NLRP3 inflammasome by inhibiting activation of caspase-1 and thus the activation of IL-1b/IL-18. Fc 11a-2 prevents the development of Dextran sulfate sodium (DSS; HY-116282C)-induced murine experimental colitis.
  • HY-B2081
    Etozolin

    W-2900A

    		 Others Metabolic Disease
    Etozolin (W-2900A) is a diuretic agent. Etozolin inhibits fluid and electrolyte reabsorption in the loop of Henle. Etozolin can be used in research of congestive heart failure, hypertension and edema.
  • HY-P1220
    Huwentoxin-IV

    		Sodium Channel Neurological Disease
    Huwentoxin-IV is a potent and selective sodium channel blocker, inhibits neuronal Nav1.7, Nav1.2, Nav1.3 and Nav1.4 with IC50s of 26, 150, 338 and 400 nM, respectively. Huwentoxin-IV preferentially blocks peripheral nerve subtype Nav1.7 by binding neurotoxin receptor site 4. Huwentoxin-IV has analgesic effects on animal models of inflammatory and neuropathic pain.
  • HY-P1220A
    Huwentoxin-IV TFA

    		Sodium Channel Neurological Disease
    Huwentoxin-IV TFA is a potent and selective sodium channel blocker, inhibits neuronal Nav1.7, Nav1.2, Nav1.3 and Nav1.4 with IC50s of 26, 150, 338 and 400 nM, respectively. Huwentoxin-IV TFA preferentially blocks peripheral nerve subtype Nav1.7 by binding neurotoxin receptor site 4. Huwentoxin-IV TFA has analgesic effects on animal models of inflammatory and neuropathic pain.
  • HY-108506
    Licarbazepine

    BIA 2-005; GP 47779

    		 Sodium Channel Neurological Disease
    Licarbazepine (BIA 2-005; GP 47779) is a voltage-gated sodium channel blocker with anticonvulsant and mood-stabilizing effects.
  • HY-100345
    AMTB hydrochloride

    		TRP Channel Cancer Neurological Disease
    AMTB hydrochloride is a selective TRPM8 channel blocker. AMTB hydrochloride inhibits icilin-induced TRPM8 channel activation with a pIC50 of 6.23. AMTB hydrochloride can be used for the research of the overactive bladder and painful bladder syndrome. AMTB hydrochloride is a non-selective inhibitor of voltage-gated sodium channels (NaV).
  • HY-P2215
    Solnatide

    AP 301

    		 Sodium Channel Metabolic Disease
    Solnatide (AP 301) is an inhaled synthetic peptide agent composed of 17 natural amino acids. Solnatide can directly activate the epithelial sodium channel. Solnatide can be used for the research of lung function.
  • HY-14945
    Remogliflozin etabonate

    GSK189075

    		 SGLT Metabolic Disease
    Remogliflozin etabonate (GSK189075) is an orally active, selective and low-affinity sodium glucose cotransporter (SGLT2) inhibitor with Ki values of 1.95 μM, 2.14 μM, 43.1 μM, 8.57 μM for hSGLT2, rSGLT2, hSGLT1, rSGLT1, respectively. Remogliflozin etabonate is a proagent based on benzylpyrazole glucoside and is metabolized to its active form, Remogliflozin, in the body. Remogliflozin etabonate exhibits antidiabetic efficacy in rodent models.
  • HY-119980
    Fluphenazine

    		Dopamine Receptor Sodium Channel SARS-CoV Infection Neurological Disease
    Fluphenazine is a potent, orally active phenothiazine-based dopamine receptor antagonist. Fluphenazine blocks neuronal voltage-gated sodium channels. Fluphenazine acts primarily through antagonism of postsynaptic dopamine-2 receptors in mesolimbic, nigrostriatal, and tuberoinfundibular neural pathways. Fluphenazine can antagonize Methylphenidate-induced stereotyped gnawing and inhibit climbing behaviour in mice. Fluphenazine can be used for researching psychosis and painful peripheral neuropathy associated with diabetes and has potential to inhibit SARS-CoV-2.
  • HY-147377
    N-Salicyloyltryptamine

    		Calcium Channel ERK Potassium Channel Guanylate Cyclase NF-κB Inflammation/Immunology Neurological Disease
    N-Salicyloyltryptamine acts on voltage-dependent Na +, Ca 2+, and K + ion channels inhibitor. N-Salicyloyltryptamine inhibits K + currents with an IC50 value of 34.6 μM (Ito). N-Salicyloyltryptamine also exhibits anticonvulsant, anti-inflammatory, analgesic, and vasorelaxation effect -.